Ligand Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 6/6
Ligand Pharmaceuticals has a total shareholder equity of $841.2M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $954.9M and $113.7M respectively. Ligand Pharmaceuticals's EBIT is $18.0M making its interest coverage ratio -3.2. It has cash and short-term investments of $219.6M.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | -3.2x |
| Cash | US$219.64m |
| Equity | US$841.18m |
| Total liabilities | US$113.69m |
| Total assets | US$954.87m |
Recent financial health updates
We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt
May 29
These 4 Measures Indicate That Ligand Pharmaceuticals (NASDAQ:LGND) Is Using Debt Reasonably Well
Jan 26We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt
Oct 21Here's Why Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt Responsibly
Jun 27Recent updates
Ligand Pharmaceuticals: Buy This Strong Growing Pharma And Get A Stake In Dozens Of Therapies
Nov 24Market Participants Recognise Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Earnings
Oct 31Ligand Pharmaceuticals: Solid Performer Performing Solidly
Jul 29Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected
Jul 18Should You Be Adding Ligand Pharmaceuticals (NASDAQ:LGND) To Your Watchlist Today?
Jun 29Subdued Growth No Barrier To Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) With Shares Advancing 27%
May 23Ligand: Buy This Pharma Royalty Aggregator To Generate Growth In Your Portfolio
Apr 30Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Not Flying Under The Radar
Dec 19Is Now The Time To Put Ligand Pharmaceuticals (NASDAQ:LGND) On Your Watchlist?
Jun 14We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt
May 29Are Investors Undervaluing Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) By 45%?
May 07These 4 Measures Indicate That Ligand Pharmaceuticals (NASDAQ:LGND) Is Using Debt Reasonably Well
Jan 26We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt
Oct 21Ligand Pharmaceuticals: Struggling Along
Sep 25Growth Investors: Industry Analysts Just Upgraded Their Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Revenue Forecasts By 11%
Aug 11Here's Why Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt Responsibly
Jun 27Financial Position Analysis
Short Term Liabilities: LGND's short term assets ($309.4M) exceed its short term liabilities ($24.8M).
Long Term Liabilities: LGND's short term assets ($309.4M) exceed its long term liabilities ($88.9M).
Debt to Equity History and Analysis
Debt Level: LGND is debt free.
Reducing Debt: LGND has no debt compared to 5 years ago when its debt to equity ratio was 74.2%.
Debt Coverage: LGND has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: LGND has no debt, therefore coverage of interest payments is not a concern.